IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科
学科主题临床医学
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial
Hu, Zhihuang1,2; Cheng, Ying3; Zhang, Hongyu4; Zhou, Caicun5; Han, Baohui6; Zhang, Yiping7; Huang, Cheng8; Chang, Jianhua9; Song, Xiangqun10; Liang, Jun11; Liang, Houjie12; Bai, Chunxue13; Yu, Shiying14; Chen, Jia15; Wang, Jie16; Pan, Hongming17; Chitkara, Denesh K.18; Hille, Darcy A.18; Zhang, Li1,2
关键词Nausea Emesis Aprepitant Emetogenic chemotherapy Standard antiemetic treatment
刊名SUPPORTIVE CARE IN CANCER
2014-04-01
DOI10.1007/s00520-013-2043-9
22期:4页:979-987
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Health Care Sciences & Services ; Rehabilitation
研究领域[WOS]Oncology ; Health Care Sciences & Services ; Rehabilitation
关键词[WOS]MODERATELY EMETOGENIC CHEMOTHERAPY ; NEUROKININ-1 RECEPTOR ANTAGONIST ; ANTIEMETIC THERAPY ; MULTIPLE CYCLES ; INDUCED EMESIS ; POSTOPERATIVE NAUSEA ; GUIDELINE UPDATE ; DEXAMETHASONE ; METAANALYSIS ; ONCOLOGY
英文摘要

Aprepitant, an oral neurokinin-1 receptor antagonist, has demonstrated improved control of chemotherapy-induced nausea and vomiting (CINV) in previous studies. This is the first phase III study to evaluate the efficacy and tolerability of aprepitant in patients receiving highly emetogenic chemotherapy (HEC) in Asian countries.

This multicenter, double-blind, placebo-controlled trial assessed the prevention of CINV during the acute phase (AP), delayed phase (DP), and overall phase (OP). Patients receiving HEC were randomized to either an aprepitant group (day 1, aprepitant 125 mg; days 2-3, aprepitant 80 mg) or a standard therapy group (days 1-3, placebo). Both groups received intravenous granisetron and oral dexamethasone. The primary end point was complete response (CR; no emesis and no use of rescue therapy) during the OP.

Of the 421 randomized patients, 411 (98 %) were assessable for efficacy; 69.6 % (142/204) and 57.0 % (118/207) of patients reported CR during the OP in the aprepitant and standard therapy groups, respectively (P = 0.007). CR rates in the aprepitant group were higher during the DP (74.0 % vs. 59.4 %, P = 0.001) but were similar during the AP (79.4 % vs. 79.3 %, P = 0.942). Toxicity and adverse events were comparable in both groups.

The addition of aprepitant to standard antiemetic treatment regimens for Chinese patients undergoing HEC provided superior CINV prevention and was well tolerated.

语种英语
WOS记录号WOS:000332505800016
资助机构Merck Sharp &amp ; Dohme Corp., a subsidiary of Merck &amp ; Co., Inc., Whitehouse Station, NJ, USA
引用统计
被引频次:16[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64769
专题北京大学临床肿瘤学院_胸部肿瘤内科
作者单位1.Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
2.Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China
3.Jilin Prov Canc Hosp, Dept Internal Med 1, Changchun, Peoples R China
4.Sun Yat Sen Univ, Dept Oncol, Affiliated Hosp 1, Zhuhai, Peoples R China
5.Tongji Univ, Shanghai Pulm Hosp, Inst Canc, Dept Oncol,Med Sch, Shanghai 200433, Peoples R China
6.Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai 200030, Peoples R China
7.Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou 310022, Zhejiang, Peoples R China
8.Fujian Med Univ, Dept Med Oncol, Fujian Prov Canc Hosp, Teaching Hosp, Fuzhou, Peoples R China
9.Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China
10.Guangxi Zhuang Autonomous Reg Tumor Hosp, Dept Chemotherapy, Nanning, Peoples R China
11.Qingdao Univ, Dept Med Oncol, Affiliated Hosp, Coll Med, Qingdao 266071, Peoples R China
12.Third Mil Med Univ, Southwest Hosp, Dept Oncol, Chongqing, Peoples R China
13.Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai 200032, Peoples R China
14.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Ctr Canc, Wuhan 430030, Hubei, Peoples R China
15.Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA
16.Jiangsu Canc Hosp, Dept Med Oncol, Nanjing 210009, Jiangsu, Peoples R China
17.Beijing Canc Hosp, Dept Thorac Med Oncol, Beijing, Peoples R China
18.Zhejiang Univ, Dept Med Oncol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
推荐引用方式
GB/T 7714
Hu, Zhihuang,Cheng, Ying,Zhang, Hongyu,et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial[J]. SUPPORTIVE CARE IN CANCER,2014,22(4):979-987.
APA Hu, Zhihuang.,Cheng, Ying.,Zhang, Hongyu.,Zhou, Caicun.,Han, Baohui.,...&Zhang, Li.(2014).Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial.SUPPORTIVE CARE IN CANCER,22(4),979-987.
MLA Hu, Zhihuang,et al."Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial".SUPPORTIVE CARE IN CANCER 22.4(2014):979-987.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hu, Zhihuang]的文章
[Cheng, Ying]的文章
[Zhang, Hongyu]的文章
百度学术
百度学术中相似的文章
[Hu, Zhihuang]的文章
[Cheng, Ying]的文章
[Zhang, Hongyu]的文章
必应学术
必应学术中相似的文章
[Hu, Zhihuang]的文章
[Cheng, Ying]的文章
[Zhang, Hongyu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。